A detailed history of Aton Ra Partners transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Aton Ra Partners holds 5,002 shares of NBIX stock, worth $627,801. This represents 1.31% of its overall portfolio holdings.

Number of Shares
5,002
Previous 5,562 10.07%
Holding current value
$627,801
Previous $625,000 5.44%
% of portfolio
1.31%
Previous 1.31%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

SELL
$106.07 - $132.76 $59,399 - $74,345
-560 Reduced 10.07%
5,002 $659,000
Q3 2023

Oct 25, 2023

SELL
$94.02 - $117.1 $121,567 - $151,410
-1,293 Reduced 18.86%
5,562 $625,000
Q2 2023

Jul 18, 2023

SELL
$89.53 - $104.87 $40,825 - $47,820
-456 Reduced 6.24%
6,855 $646,000
Q1 2023

May 05, 2023

SELL
$94.11 - $123.02 $64,747 - $84,637
-688 Reduced 8.6%
7,311 $740,000
Q4 2022

Feb 02, 2023

SELL
$106.72 - $127.06 $340,116 - $404,940
-3,187 Reduced 28.49%
7,999 $955,000
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $23,467 - $27,491
-255 Reduced 2.23%
11,186 $1.19 Million
Q2 2022

Aug 15, 2022

SELL
$75.79 - $100.07 $162,796 - $214,950
-2,148 Reduced 15.81%
11,441 $1.12 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $49,266 - $64,470
680 Added 5.27%
13,589 $1.27 Million
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $86,898 - $115,886
1,091 Added 9.23%
12,909 $1.1 Million
Q3 2021

Nov 15, 2021

BUY
$86.18 - $99.03 $78,854 - $90,612
915 Added 8.39%
11,818 $1.13 Million
Q2 2021

Aug 12, 2021

SELL
$89.43 - $102.27 $1.57 Million - $1.79 Million
-17,510 Reduced 61.63%
10,903 $1.06 Million
Q1 2021

May 17, 2021

BUY
$87.57 - $119.4 $261,484 - $356,528
2,986 Added 11.74%
28,413 $2.76 Million
Q4 2020

Feb 19, 2021

BUY
$86.91 - $108.33 $2.21 Million - $2.75 Million
25,427 New
25,427 $2.44 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Aton Ra Partners Portfolio

Follow Aton Ra Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.